Alterity Therapeutics logo

ATH - Alterity Therapeutics Share Price

A$0.02 -0.0  -4.8%

Last Trade - 17/01/20

Sector
Healthcare
Size
Micro Cap
Market Cap £9.08m
Enterprise Value £1.49m
Revenue £57.3k
Position in Universe 1247th / 1833
Bullish
Bearish
Unlock ATH Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ATH Revenue Unlock ATH Revenue

Net Income

ATH Net Income Unlock ATH Revenue

Normalised EPS

ATH Normalised EPS Unlock ATH Revenue

PE Ratio Range

ATH PE Ratio Range Unlock ATH Revenue

Dividend Yield Range

ATH Dividend Yield Range Unlock ATH Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ATH EPS Forecasts Unlock ATH Revenue
Profile Summary

Alterity Therapeutics Limited, formerly Prana Biotechnology Limited, is a development-stage medical biotechnology company. The Company is engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's disease, Huntington disease, Parkinson's disease and other neurological disorders. The Company's lead product candidates are PBT2 and PBT434. The Company's lead drug candidate PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. The Company also has advanced a drug candidate for Parkinson's disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing. Its other applications for its therapies include certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease), and a range of orphan neurodegenerative disorders.

Directors
Last Annual June 30th, 2019
Last Interim June 30th, 2019
Incorporated November 11, 1997
Public Since March 27, 2000
No. of Shareholders: n/a
No. of Employees: 15
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 860,837,432
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ATH Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ATH
Upcoming Events for ATH
Monday 27th January, 2020 Estimate
Q2 2020 Alterity Therapeutics Ltd Earnings Release
Wednesday 15th April, 2020 Estimate
Q3 2020 Alterity Therapeutics Ltd Earnings Release
Similar to ATH
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.